Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

    NHLBI Catalyze funds early-stage medical device prototypes, disease target ID, & assay development for heart, lung, blood, & sleep disorders, aiming to prep projects for further testing.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

    NHLBI Catalyze funds early research to find and validate drug therapies for heart, lung, blood, and sleep disorders, preparing them for further development.

    HHS-NIH11Due Feb 11, 2027$1,200,000

    Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

    NHLBI Catalyze program supports early-stage research to identify and characterize small molecule, biologic, and combination product therapeutic candidates for heart, lung, blood, and sleep (HLBS) disorders.

    HHS-NIH11Due Feb 11, 2027$800,000

    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

    Funds Phase I clinical trials for diagnostic/therapeutic interventions in heart, lung, blood, and sleep disorders in adults/children, allowing preclinical activities and milestone-driven support.

    HHS-NIH11Due Feb 3, 2027$5,045,000

    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)

    Supporting early phase clinical trials for heart, lung, blood, and sleep disorders in both adults and children, with applicants expected to be ready to start trials within the initial project period.

    HHS-NIH11Due Feb 3, 2027$4,545,000

    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

    This grant funds milestone-driven preclinical research to develop and advance new therapies for visual system diseases, supporting projects from early-stage lab findings through FDA IND/IDE submission readiness.

    HHS-NIH11Due Nov 16, 2029